ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma

Cancer Cell. 2023 Dec 11;41(12):2016-2018. doi: 10.1016/j.ccell.2023.11.009.

Abstract

Chimeric antigen receptor (CAR) T cell immunotherapy in solid cancer is severely limited by the absence of ideal targets. In this issue of Cancer Cell, Bergaggio et al. find that anaplastic lymphoma kinase (ALK) inhibitors can enhance the function of ALK-specific CAR T cells against neuroblastoma by increasing target density in cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Humans
  • Immunotherapy
  • Immunotherapy, Adoptive
  • Neuroblastoma* / pathology
  • Protein Kinase Inhibitors
  • Receptor Protein-Tyrosine Kinases / genetics
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Chimeric Antigen* / genetics
  • T-Lymphocytes

Substances

  • Receptors, Chimeric Antigen
  • Protein Kinase Inhibitors
  • Receptor Protein-Tyrosine Kinases
  • Receptors, Antigen, T-Cell